Markets:

Overview

News

Currencies

International

Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

18.37 -0.49 (-2.60%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Mid-Morning Market Update: Markets Open Lower; US Retail Sales Miss Estimates ↗

December 15, 2021

Following the market opening Wednesday, the Dow traded down 0.26% to 35,453.17 while the NASDAQ fell 0.62% to 15,142.70. The S&P also fell, dropping 0.28% to 4,621.34. The U.S...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates ↗

December 02, 2021

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for...

Via Benzinga

Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million ↗

November 13, 2021

Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics.

Via Talk Markets

Why Karuna Therapeutics Stock Tumbled This Week ↗

November 12, 2021

Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.

Via The Motley Fool

Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates ↗

November 09, 2021

Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in...

Via Benzinga

PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China

November 09, 2021

From PureTech Health plc

Via Business Wire

Earnings Scheduled For November 9, 2021 ↗

November 09, 2021

Companies Reporting Before The Bell • Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter. • KT (NYSE:KT) is projected to report earnings...

Via Benzinga

Week In Review: China's Hansoh Signs Two siRNA Deals Worth $1.7 Billion ↗

October 23, 2021

Hansoh announced a $1.3 billion deal to develop three siRNA candidates from London's Silence Therapeutics. In the past week, Hansoh also revealed a $456 million deal with Korea's OliX Pharma for China...

Via Talk Markets

Zai Lab Posts Encouraging Data From Early-Stage Plaque Psoriasis Trial ↗

October 21, 2021

Zai Lab Limited (NASDAQ: ZLAB) announced topline results from Phase 1b study of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque...

Via Benzinga

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

October 21, 2021

From Crescendo Biologics Ltd

Via Business Wire

Week In Review: Hansoh Signs $456 Million Deal For siRNA Products ↗

October 16, 2021

Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea's OliX Pharma. Hansoh will make an upfront payment of $6.5 million and up to...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2021 ↗

October 12, 2021

Upgrades For Callaway Golf Co (NYSE:ELY), Compass ...

Via Benzinga

Week In Review: MicroTech Medical Staging $245 Million HK IPO For Diabetes Products ↗

October 10, 2021

MicroTech Medical, a Hangzhou company that offers diabetes monitoring and treatment devices, is conducting a Hong Kong IPO that would raise $254 million at the top of the price range. LianBio has filed...

Via Talk Markets

Topics Initial Public Offering

The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More ↗

October 03, 2021

Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗

September 19, 2021

Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical...

Via Benzinga

Week In Review: China Life Science Posts $1.3 Billion In Deals ↗

August 07, 2021

Pacific Biosciences, a San Francisco Bay area company offering long-read sequencing platforms, will acquire Omniome for up to $800 million. Zai Lab and Schrödinger formed a collaboration to develop a...

Via Talk Markets

Schrödinger, Zai Lab Team Up For Cancer Program Targeting DNA Damage Response ↗

August 04, 2021

Schrödinger Inc (NASDAQ: SDGR) and Zai Lab Limited (NASDAQ: ZLAB) have collaborated to discover, develop, and commercialize oncology candidate ...

Via Benzinga

Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology

August 04, 2021

From Zai Lab Limited

Via Business Wire

Earnings Scheduled For August 9, 2021 ↗

August 09, 2021

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...

Via Benzinga

Week In Review: Kumquat Signs $2 Billion US-China Deal With Lilly For Novel Immune Drugs ↗

July 31, 2021

Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small molecule drugs that stimulate tumor-specific immune responses in cancer patients. Lilly will make a $70...

Via Talk Markets

62 Biggest Movers From Yesterday ↗

July 29, 2021

Gainers Flora Growth Corp. (NASDAQ: FLGC) surged 63.1% to close at $8.27. The Miami-based cannabis producer confirmed Tuesday it has signed a non-binding letter of intent to...

Via Benzinga

Topics Cannabis

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 28, 2021

Gainers Infinity Pharmaceuticals (NASDAQ:INFI) shares moved upwards by 45.98% to $2.22 during Wednesday's regular session. As of 12:30 EST, this security is trading at...

Via Benzinga

50 Stocks Moving In Wednesday's Mid-Day Session ↗

July 28, 2021

Gainers Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares jumped 59.9% to $2.43. Infinity Pharmaceuticals shares tumbled over 31% on Tuesday after the company highlighted the...

Via Benzinga

Week In Review: This Week's China Life Science Deals Total Over $2.5 Billion ↗

June 19, 2021

Shanghai's Zai Lab announced a four-drug immunonocology deal with MacroGenics worth over $1.4 billion. Shanghai's HutchMed (formerly Hutchison Chi-Med) is planning to raise $600 million in a Hong...

Via Talk Markets

MacroGenics, Zai Lab Ink Over $1.4B Immuno-Oncology Development Deal ↗

June 16, 2021

MacroGenics Inc (NASDAQ: MGNX) and Zai Lab Limited (NASDAQ: ZLAB) have entered into an exclusive collaboration and license agreement involving up to four...

Via Benzinga

Week In Review: Zai Lab Enters $338 Million Agreement To In-License KRAS Inhibitor ↗

June 05, 2021

Shanghai's Zai Lab in-licensed Greater China rights to adagrasib, a KRASG12C inhibitor, from Mirati of San Diego in a $338 million agreement. Mirati will receive a $65 million upfront payment and up to...

Via Talk Markets

Biotech Zai Lab Stock Sees Relative Strength Rating Jump To 83 ↗

May 14, 2021

A Relative Strength Rating upgrade for ZaiLabLimited shows improving technical performance.

Via Investor's Business Daily

Week In Review: Zai Lab Raises $750 Million In Private Placement For In-Licensed/Novel Drugs ↗

April 24, 2021

Zai Lab raised a staggering $750 million in a private placement of its dual US/Hong Kong-listed stock. It currently has a portfolio of 21 products. Zai has a market cap of $14 billion and over $1...

Via Talk Markets

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗

May 09, 2021

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.